Paclitaxel dosing equally effective in preventing breast cancer progression

Paclitaxel chemotherapy schedules equally effective for early-stage breast cancer

Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer

Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab

Nivolumab blocking PD1 in lung cancer and melanoma

Nintedanib in combination with standard second line therapy in lung cancer

The problem of unnecessary treatment of prostate cancer

Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer

Paclitaxel chemotherapy schedules are equally effective for early-stage breast cancer

Selumetinib, the first effective drug for advanced melanoma of the eye

Development and clinical trials of Z100

Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer